{"id":"W4388247185","doi":"10.1016/j.esmoop.2023.102049","title":"Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma","year":2023,"lang":"en","type":"editorial","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre","funders":"Sirtex Medical; Eisai; Ipsen; BeiGene; Sociedad Española de Oncología Médica; Incyte; Horizon 2020 Framework Programme; Boston Scientific Corporation; AstraZeneca; Mylan; Servier; European Commission; Pfizer; Amgen","keywords":"Fibroblast growth factor receptor; Cancer research; PI3K/AKT/mTOR pathway; Medicine; Cancer; Protein kinase B; Intrahepatic Cholangiocarcinoma; Oncology; Internal medicine; Fibroblast growth factor; Receptor; Biology; Signal transduction; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000407653,0.0003300665,0.0007396798,0.0005134827,0.000242155,0.0008574001,0.0002958471,0.0007826755,0.01252123],"category_scores_gemma":[0.0005334461,0.00008210585,0.0007389178,0.0004793365,0.0001924309,0.0004268989,0.0003400244,0.00152221,0.003917279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000673774,"about_ca_system_score_gemma":0.0006197314,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00081254,"about_ca_topic_score_gemma":0.002862221,"domain_scores_codex":[0.9997701,0.00004498347,0.00001880758,0.00002258208,0.00007411465,0.00006932142],"domain_scores_gemma":[0.9998271,0.0000291644,0.00002956971,0.000008910433,0.0000478719,0.00005744075],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004193245,0.0002323977,0.001802268,0.003550083,0.000307234,0.001541997,0.00009926403,0.0007734252,0.01751062,0.00345848,0.2213655,0.7451655],"study_design_scores_gemma":[0.004114817,0.002324564,0.01233654,0.001579207,0.0003988402,0.006820633,0.00008371008,0.001024671,0.009148749,0.003160151,0.9589523,0.0000558776],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"editorial","genre_scores_codex":[0.106277,0.6037058,0.004382798,0.04962686,0.006545282,0.0005485034,0.01501286,0.002275995,0.2116249],"genre_scores_gemma":[0.5706967,0.2614485,0.004978279,0.03189286,0.003382599,0.0007685435,0.02757666,0.0003848631,0.09887102],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.01252123,"threshold_uncertainty_score":0.0418877,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0439699449041167,"score_gpt":0.3597103993650207,"score_spread":0.315740454460904,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}